尼罗替尼
髓系白血病
突变
癌症研究
酪氨酸激酶
伊马替尼
医学
酪氨酸激酶抑制剂
抗药性
突变体
达沙替尼
抗性突变
生物
遗传学
基因
内科学
癌症
逆转录酶
受体
聚合酶链反应
作者
Zafar Iqbal,Muhammad Absar,Amer Mahmood,Aamer Aleem,Mudassar Iqbal,Abid Jameel,Tanveer Akhtar,Sajjad Karim,Mahmood Rasool,Zeenat Mirza,Muhammad Usman Khalid,Afia Muhammad Akram,Muhammad Farooq Sabar,Ahmad Mukhtar Khalid,Khaled Aljarrah,Janhangir Iqbal,Ijaz Hussain Shah,Nawaf Alanazi
标识
DOI:10.31557/apjcp.2020.21.12.3517
摘要
Objective BCR-ABL fusion oncogene is the hallmark of chronic myeloid leukemia (CML), causing genomic instability which leads to accumulation of mutations in BCR-ABL as well as other genes. BCR-ABL mutations are the cause of tyrosine kinase inhibitors (TKIs) resistance in CML. Recently, compound BCR-ABL mutations have been reported to resist all FDA approved TKIs. Therefore, finding novel compound BCR-ABL mutations can help and clinically manage CML. Therefore, our objective was to find out novel drug-resistant compound BCR-ABL mutations in CML and carry out their protein modelling studies. Methodology Peripheral blood samples were collected from ten imatinib resistant CML patients receiving nilotinib treatment. BCR-ABL transcript mutations were investigated by employing capillary sequencing. Patient follow-up was carried out using European LeukemiaNet guidelines. Protein modeling studies were carried out for new compound mutations using PyMol to see the effects of mutations at structural level. Results A novel compound mutation (K245N mutation along with G250W mutation) and previously known T351I utation was detected in two of the nilotinib resistance CML patients respectively while in the rest of 8 nilotinib responders, no resistant mutations were detected. Protein modelling studies indicated changes in BCR-ABL mutant protein which may have negatively impacted its binding with nilotinib leading to drug resistance. Conclusion We report a novel nilotinib resistant BCR-ABL compound mutation (K245N along with G250W mutation) which impacts structural modification in BCR-ABL mutant protein leading to drug resistance. As compound mutations pose a new threat by causing resistance to all FDA approved tyrosine kinase inhibitors in BCR-ABL+ leukemias, our study opens a new direction for in vitro characterization of novel BCR-ABL compound mutations and their resistant to second generation and third generation TKIs.
科研通智能强力驱动
Strongly Powered by AbleSci AI